118 related articles for article (PubMed ID: 10671790)
1. Serum anti-p53 antibodies and p53 protein status in the sera and tumors from bladder cancer patients.
Morita T; Tachikawa N; Kumamaru T; Nukui A; Ikeda H; Suzuki K; Tokue A
Eur Urol; 2000 Jan; 37(1):79-84. PubMed ID: 10671790
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
3. The correlation of p53 protein overexpression and p53 antibodies in serum of patients with transitional cell carcinoma of the urinary bladder.
Wunderlich H; Hindermann W; Hüller M; Reichelt O; Werner W; Schubert J; Kosmehl H
Urol Int; 2000; 64(1):13-7. PubMed ID: 10782026
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
5. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
[TBL] [Abstract][Full Text] [Related]
6. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma.
Bourhis J; Lubin R; Roche B; Koscielny S; Bosq J; Dubois I; Talbot M; Marandas P; Schwaab G; Wibault P; Luboinski B; Eschwege F; Soussi T
J Natl Cancer Inst; 1996 Sep; 88(17):1228-33. PubMed ID: 8780633
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors.
Watanabe J; Nishiyama H; Kawanishi H; Ito M; Kamoto T; Ogawa O
J Urol; 2005 Jul; 174(1):73-5. PubMed ID: 15947581
[TBL] [Abstract][Full Text] [Related]
8. Importance of serum p53 antibodies during follow-up after treatment of invasive bladder tumors.
Gumus E; Demirel G; Tanriverdi O; Horasanli K; Ozmen G; Miroglu C
Urol Int; 2004; 72(4):292-8. PubMed ID: 15153725
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of nuclear p53 and tumor progression in bladder cancer.
Esrig D; Elmajian D; Groshen S; Freeman JA; Stein JP; Chen SC; Nichols PW; Skinner DG; Jones PA; Cote RJ
N Engl J Med; 1994 Nov; 331(19):1259-64. PubMed ID: 7935683
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
[TBL] [Abstract][Full Text] [Related]
11. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
Shimizu K; Ueda Y; Yamagishi H
Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
[TBL] [Abstract][Full Text] [Related]
12. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
15. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
18. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
19. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
[TBL] [Abstract][Full Text] [Related]
20. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]